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Objective: The European Society on Clinical and Economic aspects of Osteoporosis and Osteoarthritis
(ESCEO) organised a working group to evaluate the need for updating the current European guideline on
clinical investigation of drugs used in the treatment of osteoarthritis (OA).
Design: Areas of potential attention were identiﬁed and the need for modiﬁcations, update or clariﬁ-
cation was examined. Proposals were then developed based on literature reviews and through a
consensus process.
Results: It was agreed that the current guideline overall still reﬂects the current knowledge in OA,
although two possible modiﬁcations were identiﬁed. The ﬁrst relates to the number and timing of
measurements required as primary endpoints during clinical trials of symptom-relieving drugs, either
drugs with rapid onset of action or slow acting drugs. The suggested modiﬁcations are intended to take
into consideration the time related clinical need and expected time response to these drugs e i.e., a more
early effect for the ﬁrst category in addition to the maintenance of effect, a more continuous beneﬁt over
the long-term for the latter e in the timing of assessments.
Secondly, values above which a beneﬁt over placebo should be considered clinically relevant were
considered. Based on literature reviews, the most consensual values were determined for primary
endpoints of both symptom-relieving drugs (i.e., pain intensity on a visual analogue scale (VAS)) and
disease-modifying drugs (i.e., radiographic joint-space narrowing).J.-Y. Reginster, Department of
University of Liege, CHU Sart
er).
r Ltd and Osteoarthritis Research Society International. This is an open access article under the CC BY-NC-ND license
J.-Y. Reginster et al. / Osteoarthritis and Cartilage 23 (2015) 2086e2093 2087Conclusions: This working document might be considered by the European regulatory authorities in a
future update of the guideline for the registration of drugs in OA.
© 2015 The Authors. Published by Elsevier Ltd and Osteoarthritis Research Society International. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
Osteoarthritis (OA) is a common, slowly progressive condition
that may affect all joint structures, and is a major cause of pain and
chronic disability in the elderly1. Current treatment includes non-
pharmacological and pharmacological therapies that are taken
into account in a recent algorithm developed to advise on the
possible stepwise approach to the sequence of interventions2.
Symptomatic drugs are usually divided into drugs with a rapid
onset of action such as paracetamol or other analgesics and non-
steroidal anti-inﬂammatory drugs (NSAIDs) e (being either non-
selective or selective COX-2 inhibitors) e or intra-articular in-
jections of corticosteroids, and Symptomatic Slow Acting Drugs for
OA (SYSADOAs) such as glucosamine and chondroitin sulfate or
intraarticular hyaluronic acid. Drugs with potential beneﬁcial effect
on the joint structure (Disease Modifying OsteoArthritis Drugs,
DMOADs) may be developed in the future: these may or may not
have a direct effect on symptoms and they may delay the disease
process, as preliminarily suggested by currently available SYSA-
DOAs showing some hints of modiﬁcation of joint structure3,4,5.
A ﬁrst European regulatory document aimed at providing advice
for the development of drugs in OA was issued in 19986. The latest
version of the Committee for Medicinal Products for Human Use
(CHMP)/European Medicines Agency (EMA) guidance7, adopted in
2010, is a revision of that document.
The ﬁrst version of the guideline6 was derived from a report by
the Group for Respect of Ethics and Excellence in Sciences (GREES)8.
This group has been thereafter providing recommendations for an
update based on a critical analysis of the available science9e11.
A substantial part of these proposals were taken into account in
the 2010 current version of the CHMP/EMA guidance7.
Several elements of the guideline are the subject of much
debate. They are mainly related to the cut-off values that should
deﬁne a clinically relevant symptomatic or structural improvement
and to the timing of assessments that should be collected
throughout conﬁrmatory clinical trials.
For this reason, under the auspices of the European Society on
Clinical and Economic aspects of Osteoporosis and Osteoarthritis
(ESCEO), a special section of the GREES was convened in May 2014
to discuss these issues in the light of recent data and expert opinion.
The consensus view, which might be possibly considered in future
guidelines, is presented in this discussion paper.
Methods
As in previous initiatives and publications, the GREES/ESCEO
working group consisted of clinical scientists expert in the ﬁeld of OA
in academia and consulting for drug development within the phar-
maceutical industry, and representatives of national or European
licensing authorities giving their contribution on a personal basis.
As a general methodology, the group reviewed the current
version of the CHMP/EMA guideline in detail7.
The members of the working group were asked to assess the
possible need for revision of the guideline in view of their knowl-
edge of the ﬁeld and of the clinical literature, in order to identify the
areas of potential attention. The group judged that there was no
need to revise any of the ﬁrst four sections within the CHMP/EMAdocument (including disease deﬁnition, drug categories and pa-
tient selection). Conversely, there was general consensus that
speciﬁc parts within the methods for assessing efﬁcacy section
(Section 5) for both symptom modifying and structure modifying
drugs, with particular respect to the clinical relevance of the
changes on the primary endpoint(s) and the timing of assessment,
may be in need of clariﬁcation. This would inevitably affect also the
section on the design of the studies (Section 6.2) with particular
regard to conﬁrmatory trials, while the guideline sections on ‘early
studies in man’ (Section 6.1) or the ‘clinical safety evaluation’
(Section 7) were not explicitly covered by the discussion.
Members of the group (SR, OB and GH-B) were therefore asked
to prepare a full review of the literature on these topics and to
present the results at the May 2014 meeting. After the pre-
sentations, a comprehensive discussion was hold within the group
and shared conclusions were reached.
Results
Table I summarizes the proposed changes to the current
guideline document, as extensively reported below.
Primary endpoint and design of clinical studies of symptom
modifying drugs
Symptom modifying drugs act on pain and potentially on
functional disability. According to the CHMP guideline, Phase III
pivotal studies should have a randomised, double-blind, parallel
group design. A three-arm study with placebo and a most appro-
priate active comparator is recommended for symptom modifying
drugs: the nature of the active comparator can be discussed be-
tween the regulatory authority and the sponsor e.g., in a scientiﬁc
advice procedure. Long-term efﬁcacy data (e.g., on an open label
extension) as well as data after stopping therapy should be pro-
vided. Importantly, the absence of deleterious effects on joint
structure should be established from imaging (e.g., radiographic)
data obtained over at least one year.
The recommended primary endpoint for clinical development of
symptom modifying drugs is pain attributable to the target joint.
Pain referring to a recent period, ideally the past 24 or 48 h, should
be self-assessed by the patient using a validated method (e.g., the
visual analogue scale-VAS, Likert scale…). Validated multidimen-
sional tools with pain subscale index are also acceptable. Functional
disability may be considered as an important co-primary endpoint,
again with validated disease-speciﬁc and joint-speciﬁc in-
struments. However, if functional disability is not a co-primary
endpoint and beneﬁt is only shown for pain, at least the absence
of deterioration of physical function should be demonstrated.
In the opinion of the working group, some speciﬁc clariﬁcations
and recommendations were considered necessary and are given
below for the development of drugs with rapid onset of actions and
SYSADOAs, respectively.
Symptom modifying drugs with rapid onset of action
The current guideline recommends that the primary endpoint,
i.e., the change from baseline in pain intensity and optionally
Table I
Proposedmodiﬁcations to the current CHMP/EMA guideline on the clinical investigation of medicinal products used in the treatment of OA (CPMP/EWP/784/97). Sections 1e4
and 7 do not require modiﬁcations
Current content Proposed modiﬁcation
5. Methods to assess efﬁcacy
5.1 Medicinal products intended to improve symptoms
Primary endpoint
 Pain attributable to the target joint is the primary endpoint.  Unchanged
 Pain self-assessment by a validatedmethod (e.g., VAS, NRS, Likert) separately on
motion at rest, or validatedmultidimensional tools subscale index, referring to a
recent past (e.g., 24e48 h), as absolute difference vs baseline.
 Unchanged
 The difference vs placebo should be predeﬁned and justiﬁed based on published
trials.
 A rounded MPCI 10 mm average value on a 100 mm VAS is acceptable as
threshold for clinically signiﬁcant difference vs placebo at the patient group
level.
 Functional disability co-primary optionally, or at least show no deterioration.  Unchanged
Secondary endpoints
 Course of pain intensity (e.g., AUC).  Unchanged
 Percentage of responders per predeﬁned deﬁnition (including PASS, MCII,
OARSI criteria).
 Responder criteria are important at the individual patient level: MCII is the
preferred concept and PASS is helpful for assessing maintenance of
improvement; OARSI/OMERACT criteria as alternative, but do not distinguish
between pain and function. Clinically relevant improvement at a 10e20%
difference vs placebo depending on drug class (SYSADOA and symptomatic
drugs with rapid onset of action, respectively).
 Other secondary endpoints  Unchanged
5.2 Medicinal products intended to slow or prevent structural damage
 Radiographic JSN as primary endpoint, with technical recommendations for
assessment.
 Unchanged
 MRI as potential alternative surrogate endpoint still subject to validation,
similarly to biochemical markers.
 Watch out for ongoing initiatives to qualify biochemical markers and
especially MRI as an imaging biomarker offering surrogacy over shorter
periods and in smaller trials than with JSN.
6. Strategy and design of clinical trials
6.1 Early studies in Man  Unchanged
6.2 Therapeutic conﬁrmatory studies
6.2.1 Study design
Modiﬁcation of symptoms
 Studies should have randomized, double-blind, three-arm (placebo and active
comparator) design.
 Unchanged
 Primary efﬁcacy endpoint at a time-point showing maximum effect vs placebo,
with maintenance conﬁrmed for at least 3 months, for symptom modifying
drugs with rapid onset of action.
 Most trials powered for primary endpoint signiﬁcance vs placebo at 12e13
weeks, but several patients may need very short-term pain relief (2e4
weeks).
 Three classes among drugs with rapid onset of action: a) very short-term pain
relief, primary endpoint at 2e4 weeks (no worsening at 12 weeks); b) both
very short-term andmaintenance of pain relief, co-primary end-points at 2e4
and 12 weeks (issues in powering the studies); c) relief of persistent pain,
primary endpoint at 12 weeks (effects at 2e4 weeks should be described).
 For SYSADOA, evaluation after at least 6e12 months.  Pain intensity at multiple time-points, at least two consecutive assessments
(4 weeks apart) or 50% of the assessments (including the last one in either
case), over 6e12 months.
 Structural changes to be monitored for at least one year to exclude deleterious
effects on the joint.
 Unchanged
 Data after stopping therapy should be obtained.  Unchanged
Modiﬁcation of structure
 Studies should have randomized, double-blind, parallel group design, not
shorter than 2 years
 Unchanged
 Clinical endpoints, e.g., time to virtual or actual joint replacement, preferable. If
structural changes (JSN) are primary endpoint, magnitude of clinically relevant
effect should be predetermined.
 Radiographic JSN 0.5 mm corresponds to the lowest difference exceeding
the measurement error and is a relevant threshold to demonstrate activity
at the individual patient level, in that signiﬁcantly correlates with recourse to
TJR in several studies. At the patient group level, these studies have shown
that themean reduction in JSN ranges from 0.10 to 0.36 mm vs placebo over 2
e3 years.
6.2.2 Choice of control  Unchanged
6.2.3 Concomitant interventions  Unchanged
Abbreviations: NRS ¼ Numeric Rating Scale; AUC ¼ Area Under the Curve; MCII ¼Minimum Clinically Important Improvement; SYSADOA ¼ Symptomatic Slow Acting Drugs
in Osteoarthritis; TJR ¼ Total Joint Replacement.
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to show the maximum effect over placebo. However, the guideline
adds that the maintenance of effect should be evaluated after at
least 3 months. Consequently, most clinical trials aiming at
demonstrating the beneﬁt of drugs rapidly acting on symptoms of
OA are powered to reach statistical signiﬁcance for the comparison
of the drug vs placebo at 12 or 13 weeks only12e16.
Although OA is a chronic disease, it shows ﬂuctuating levels of
pain over time. For this reason, heterogeneous results for non-selective or COX-2 selective inhibitors NSAIDs have been shown
in clinical trials17 and several studies have failed to show clinically
relevant outcomes measured at 3 months18,19. Moreover, from the
patient's perspective it would seem appropriate to have different
therapeutic options, including a treatment with a demonstrated
acute analgesic effect in addition to maintenance of improvement.
In systematic reviews of randomised clinical trials in knee OA
patients and as acknowledged by the current CHMP guideline, the
time-point of maximum effect over placebo was determined to be
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intra-articular steroids injections and topical NSAIDs, respec-
tively17,20. Indeed, these drug classes are intended to rapidly
decrease pain/inﬂammation during the symptomatic phases of OA.
Furthermore, in clinical trials, the possibility of detecting a
symptomatic beneﬁt over placebo is more likely early in the course
of the study than at 3 months, due to the self-healing effect: in OA
clinical trials, placebo responses on pain have been shown to be
considerable21,22 and may increase over time23. Last but not least,
several patients may actually need drugs that provide very short-
term pain relief. Therefore, the clinical relevance of this time-
point at 3 months appears questionable for this class of drugs,
especially for those with a particularly fast and relevant onset of
action, that in several instances may even better serve patient's
needs. Thus, the group felt it may be at least as important to
demonstrate a decrease in pain intensity in the ﬁrst weeks of
treatment as it is after 3months, as long as the characteristics of the
new drug indicate that this is a potentially achievable target. Two to
4weeks appear as a reasonable target for the demonstration of pain
reduction, depending on the drug tested.
Theworking group proposal is that the beneﬁt of most analgesic
drugs over placebo on pain assessed at 2e4 weeks after the initi-
ation of treatment might be considered an alternative primary
endpoint. The currently recommended beneﬁt at 3 months may
remain a co-primary endpoint as evidence for the maintenance of
the effect of the drug, or in exceptional cases even as a secondary
endpoint if appropriately justiﬁed (e.g., depending on the indica-
tion claimed, or the characteristics of the drug and keeping in mind
that the extent of the difference between groups may be smaller at
3 months than at 2e4 weeks for the reasons above, thus with issues
in appropriately powering the studies).
Drugs whose mechanism of action suggests a strong mainte-
nance of effects, may retain the currently recommended primary
endpoint at 3 months (but the effects after 2e4 weeks should be
described). In such a way, there may be three classes within
symptom modifying drugs with rapid onset of action: a) those that
provide very short-term pain relief, with trial primary endpoint
after 2e4 weeks (and at least no worsening over placebo on 12-
week data collected as secondary endpoint); b) those providing
both very short-term pain relief and maintenance of such effect
after 12 weeks (two co-primary endpoints); c) those whose pri-
mary endpoint for pain relief is at 12 weeks, as currently recom-
mended (but whose effects after 2e4 weeks should be described).
Appropriate classiﬁcation should be reﬂected in the drug labelling.
OA pain intensity should be measured by patient's self-
assessment with validated methods such as the Visual Analogue
Scale (VAS), which is enough sensitive to distinguish small differ-
ences. The guideline requires the demonstration of a statistically
signiﬁcant and a clinically meaningful superiority vs placebo on
pain intensity to justify efﬁcacy. However, there is no further
indication of where this clinically relevant superiority threshold
should be set at a patient group level or at an individual patient
level.
At the patient group level, the Minimum Perceptible Clinical
Improvement (MPCI) could be considered: a value of 9.7 mm on the
100 mm normalised pain subscale of a multidimensional tool such
as the WOMAC (Western Ontario and McMaster Universities) in-
dex24 (a copyrighted instrument, therefore not publicly available)
has been shown to represent the MPCI in patients with knee or hip
OA25. Thus, a rounded 10 mm value on a 100 mm pain VAS is
accepted by the scientiﬁc community as a threshold for a clinically
signiﬁcant difference as compared with placebo26. Indeed, it has
been shown to be an achievable target for symptom modifying
drugs with rapid onset of action, e.g., NSAIDs at the peak of their
effects after 2e4 weeks of treatment20. Such threshold may be usedas primary outcome in pivotal trials and thus for sample size
calculation. Clearly, the ﬁnal decision on product approval will
depend on the overall assessment of the beneﬁt and harm related
to the new speciﬁc agent.
At the individual patient level, the most widely accepted and
preferred concept to deﬁne a responder is the Minimal Clinically
Important Improvement (MCII, i.e., “feeling better”)27,28. A
responder rate based on the MCII could be chosen as an important
secondary endpoint. Also, the Patient Acceptable Symptom State
(PASS, i.e., “feeling good”) could be used to calculate the rate of
responders29 especially when assessing maintenance of improve-
ment after 3 months. Another method for determining a clinically
relevant responder would be to use the OARSI/OMERACT responder
criteria30. However, they cannot distinguish between pain and
function.
The difference between the rates (percentages) of deﬁned re-
sponders between test and placebo group should show a relevant
clinical beneﬁt for a substantial part of treated patients to justify
the treatment. Such difference should be pre-determined and at
least approximately 20% over placebo.
Further improvement of study design could be reached by
requiring a ﬂaring design in knee OA patients31 and considering the
documented differences in the outcome between knee and hip OA
by assessing the locations separately19.
SYSADOAs
The current guideline recommends that for SYSADOAs the pri-
mary endpoint for symptoms should be assessed after at least 6e12
months of treatment. It is unclear whether the extent of improve-
ment after such a long treatment course should be similar to that
suggested for rapidly acting symptomatic agents and whether a
single assessment at the end of treatment is sufﬁcient.
With respect to the latter, the position of the working groupwas
that the assessment of pain intensity at multiple time-points,
reﬂecting a sustained clinical beneﬁt, would be more appropriate
and relevant for this class of drugs than a rather random outcome
measurement of improvement at only one single time point.
Insofar as OA may be associated with remitting and relapsing
symptoms, intermediate measurements should be taken into ac-
count in the evaluation of slow-acting drugs, as well as consistency
between various assessments.
This statement is in accordance with data showing that the
consistency of pain at two time points, not only its severity, can
predict the need for total knee replacement32. The association was
consistent across each level of pain severity. In line with this
concept of consistency between multiple measurements, the sus-
tainability and persistence of symptoms were considered impor-
tant components for “virtual joint replacement” (VJR), a composite
index proposed as a surrogate outcome for OA progression in
clinical trials33.
The multiplicity of assessments however raised several issues,
including the questions of the number of measurements and when
they should be performed. In 6e12-month clinical trials, the
number of assessments of pain and function is generally from 3 to
6, distributed over the treatment period in the most appropriate
manner according to the characteristics of the medicinal product
and of the trial.
The group suggested that within the context of conﬁrmatory
trials for SYSADOAs, a statistically signiﬁcant improvement should
be detected at least on the last two consecutive assessments as long
as they are sufﬁciently spaced, e.g., not less than 4 weeks apart.
Alternatively, a signiﬁcant improvement might be seen on at least
50% of the assessments including the last one. In any case, there
should be no clinically relevant worsening at any of the time points.
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the results is that themultiplicity of measurements should be taken
into consideration in the preparation of the statistical analysis
plan34.
Also for SYSADOAs, the current CHMP-guideline recommends
that the mean difference in the change in pain intensity vs placebo
should be statistically signiﬁcant and clinically relevant. It is
generally admitted that the expected extent of improvement is
smaller with SYSADOAs than with drugs with rapid onset of ac-
tion35,36. Published clinical trials show symptomatic improvement
in the 5e6 mm range on a 100 mm VAS3742. Average changes in
this range translated in a clinically relevant higher proportion of
responder patients according to MCII, PASS, or OARSI/OMERACT
criteria. The working group suggested at least 5 mm as a clinically
relevant threshold for a SYSDAOA in the difference with placebo at
the patient group level, also considering that the required sustained
beneﬁt might increase the precision of measurements (see above),
that such an effect would allow the control of the disease symp-
toms over much longer treatments and ﬁnally, in view of the
generally better safety of SYSADOAs compared with faster acting
medications. At the individual patient level, the same parameters
considered for symptommodifying drugswith rapid onset of action
should be used for calculating responder rates, aiming at a differ-
encewith placebo in the 10e20% range as suggested in pivotal trials
of existing SYSADOA42.
Primary endpoint and design of Disease Modifying Drugs for
Osteoarthritis (DMOADs)
Structural modiﬁcation of the joint is considered to be the most
important determinant of disease progression. Joint Space Nar-
rowing (JSN),measured on conventional X rays, is currently the only
validated primary outcome measure to show progression of OA7,43.
The surrogacy of JSN has been established in 8-year studies where it
has been shown to correlate with the need for joint replacement in
knee OA44,45. It is assumed that this could also be valid for hip OA.
Theworking group agrees therefore on the current guideline stating
that radiographic JSN is an acceptable surrogate outcome measure
for OA disease modiﬁcation and is still the gold standard compared
with othermethods includingmagnetic resonance imaging (MRI) or
biochemicalmarkers. The group also agrees on the current technical
recommendations within the guideline for appropriate radiological
assessment. However, if a clear consensus admits that JSN is the
most appropriate structural measure46,47, a threshold value above
which a reduction of JSN should be considered as clinically relevant
has not been validated. Nevertheless, a minimum radiographic JSN
of 0.5 mm or more over the duration of the trial (i.e., 2e3 years) in
the individual patient has been suggested to be a relevant threshold
to demonstrate efﬁcacy26,48. This value corresponds mostly to the
lowest difference in joint space width exceeding the measurement
error: while, pragmatically, the measurement error should be
study-speciﬁc, the current guidelines state that the magnitude of
the drug effect should be predetermined based on previously
established ﬁndings. The group agrees on this statement (also in
view of the need of predetermining the sample size of the trial) and
it appears therefore logical to base the choice on the available
literature. In this respect and notably, patients with radiographic
minimum JSN 0.5 mm over 3 years have a statistically signiﬁcant,
three-to fourfold increase in risk of joint replacement over up to 8
years11,44,. However, none of the considered thresholds of mean JSN
(0.2e0.8 mm) was signiﬁcantly related to the clinical outcome. In a
number of studies, individual patients considered having a clinically
relevant radiographic progression are those with a minimum JSN
0.5 mm5,4852. Conversely, it is more difﬁcult to determine what
should be a clinically relevant difference in JSN at a patient grouplevel, sincemany patients do not vary at all, even during a 2e3 years
period of observation, and since the distribution of radiographic
joint space changes does not follow a Normal law. Published clinical
trials generally show a group mean reduction of JSN with glucos-
amine3,4,50, chondroitin sulfate5,50,53 or strontium ranelate49
ranging from less than 0.10 to 0.36 mm over 2 or 3 years. Such
average changes are clinically relevant in that they seem to predict
total joint replacement over longer periods of observation54. As
discussed above for SYSADOA pain relief assessments, the consis-
tency of the trend of JSN over the duration of the trial could be
important to consider, as it has been shown that taking into account
more measurements and not only the last one, may be more rele-
vant as a predictive tool of future knee surgery in the individual
patient.44
While radiographic JSN is the currently accepted primary
endpoint at the regulatory level for a DMOAD, it is acknowledged
that it is an imperfect surrogate of disease progression. First of all, it
may reﬂect modiﬁcations in other structures, e.g., meniscal extru-
sion and degeneration, while not addressing changes at other joint
tissues, e.g., synovitis or bone marrow lesions. In addition, small
sensitivity to change may require several hundred patients in 2e3
year trials to show relevant changes over placebo. For this reason
initiatives are in progress such as the one by the Foundation for NIH
OA Biomarkers Consortium55 to qualify new biochemical or imag-
ing biomarkers that may be predictive of radiographic (and pain)
progression over shorter treatment periods and in smaller scale
trials. In particular, MRI may become the imaging modality of
choice in the future if its validity and responsiveness is proven. MRI
measures currently investigated include quantitative cartilage
morphometry, bone marrow lesions and other joint structure
changes on semi-quantitative analysis, bone shape/attrition and
subchondral bone area55.
Discussion
The current CHMP European guidance on clinical investigation
of drugs for the treatment of OA overall is still in line with the
current scientiﬁc knowledge and only a few points that deserve
discussion were identiﬁed. They mainly relate to the number and
timing of measurements of the primary endpoints performed
during clinical trials with symptom modifying medicinal products
with rapid onset of effect and SYSADOA, and the need to deﬁne
more precisely the required clinically relevant beneﬁt thresholds
for both symptom modifying and structure modifying agents.
For symptom-relieving drugs, the guideline recommends that
an improvement in pain intensity should be demonstrated pri-
marily at 3 months for drugs with rapid onset of action and at 6
months or 12 months for SYSADOAs. The suggested modiﬁcations
are intended to take into account the expected time-related main
clinical need and time response of these drugs e i.e., a more acute
effect for the ﬁrst class of drugs in addition tomaintenance of effect,
a more sustained effect for the lattere in the timing of assessments.
For drugs providing very short-term pain relief, symptomatic
beneﬁt should be demonstrated as primary endpoint after 2e4
weeks of treatment, to be possibly adapted to the pharmacokinetic
and pharmacodynamic characteristics of the drug tested, with the
maintenance of efﬁcacy after a 3-month treatment period as a co-
primary endpoint or as a secondary endpoint if appropriately
justiﬁed. In the important subset of patients with persistent pain,
the primary endpoint should continue to be collected at 3 months,
thus giving preference to maintenance of effects. The exact product
characteristics should be described in the drug labelling. As dif-
ferences in the extent of pain reduction between knee and hip OA
patients are identiﬁed this should be considered by appropriately
assessing these patients separately.
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time points to better show sustained beneﬁt. Signiﬁcant beneﬁt
over placebo should be shown on at least two consecutive assess-
ments including the last one over a 6e12-month treatment, or 50%
of the assessments including the last one with no clinically relevant
worsening at any time point.
A second aspect of the discussions concerned the threshold
value above which a beneﬁt over placebo should be considered as
clinically relevant. Although none of the proposed thresholds is
ofﬁcially validated and further conﬁrmatory data are needed, the
most consensual values based on a literature reviewwere identiﬁed
for each class of drugs. For symptomatic drugs, the mean difference
of changes in pain intensity between the active drug and placebo at
the patient group level should be at least 10 mm on a 100 mm VAS
or on the normalised pain subscale of an appropriate multidi-
mensional tool (e.g., the WOMAC index) for a drug with a rapid
onset of action. For a SYSADOA such average difference should be at
least 5 mm, but it should be shown at repeated time points. At the
individual patient level, several responder criteria have been pro-
posed as secondary endpoints, including preferentially the MCII, or
the PASS (especially for documenting maintenance of effects), or
the OARSI/OMERACT criteria. The difference with placebo in
responder rate should be between 10% and 20% depending on the
drug class (SYSADOA or rapid onset of action, respectively). For
DMOADs, the reduction in the proportion of patients with radio-
graphic minimum JSN of more than 0.5mm over the duration of the
trial is suggested as a relevant threshold to demonstrate efﬁcacy at
the individual patient level. Conversely, it is more difﬁcult to pro-
pose an average difference with placebo in the change from base-
line at the patient group level, although available trials3,4,5,49,50,53
show that this may range from less than 0.10 to 0.36 mm over
2e3 years and be clinically relevant54. New initiatives are ongoing55
that may establish MRI as a better surrogate of OA progression.
Much remains to be established in OA. The research agenda
includes better understanding of underlying mechanisms of the
disease, and consensus on the deﬁnition of clinical outcomes.
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